Biochemical characterization of x-ray contrast media

Investigative Radiology

Volumn 31, Issue 1, 1996, Pages 30-42

  Krause, Werner ^a   Niehues, Daniela ^a  

^a BAYER PHARMA AG   (Germany)

Author keywords

biochemical parameters; complement activation; Contrast media; histamine release; in vitro tests; incompatibility; lysozyme; partition coefficient; protein binding

Indexed keywords

CONTRAST MEDIUM; IODIXANOL; IOHEXOL; IOMEPROL; IOPAMIDOL; IOPENTOL; IOPROMIDE; IOTETROL; IOTROLAN; IOVERSOL; MEGLUMINE DIATRIZOATE; MEGLUMINE IOXAGLATE PLUS SODIUM IOXAGLATE; UNCLASSIFIED DRUG;

ALLERGENICITY; ARTICLE; COMPLEMENT ACTIVATION; DRUG MONITORING; DRUG PROTEIN BINDING; DRUG SOLUBILITY; ENZYME INHIBITION; HISTAMINE RELEASE; HYDROPHOBICITY; PARTITION COEFFICIENT; PRIORITY JOURNAL;

EID: 0030058891     PISSN: 00209996     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004424-199601000-00006     Document Type: Article

References (49)

1. Silvay-Mandeau, Meissner C, Wenzel-Hora BI. Clinical safety assessment of iotrolan 280 in European clinical studies. Eur Radiol 1995;5:S85-S88.
2. Scholtan W. Über die Bindung der Langzeit-Sulfonamide an die Senimeiweißkörper. Makromol Chem 1962;54:24.
3. Staks T, Schuhmann-Giampieri G, Frenzel T, Weinmann HJ, Lange L, Platzek J. Pharmacokinetics, dose proportionality, and tolerability of gadobutrol after single intravenous injection in healthy volunteers. Invest Radiol 1994;29:709-15.
4. Adam G, Neuerburg J, Spuntrup E, Mühler A, Scherer K, Günther RW. Dynamic contrast-enhanced MR imaging of the upper abdomen: Enhancement properties of gadobutrol, gadolinium-DTPA-polylysine, and gadolinium-DTPA-cascade-polymer. Magn Res Med 1994;32:622-628.
5. Krause W, Schuhmann-Giampieri G, Staks Th, Kaufmann J. Dose proportionality of iopromide pharmacokinetics and tolerability after IV injection in healthy volunteers. Eur J Clin Pharmacology 1994;46(4):339-343.
6. Faraj BA, Gottlieb GR, Camp VM, Kutner M, Lolies P. Development of a sensitive radioassay of histamine for in vitro allergy testing. J Nucl Med 1984;25:56-63.
7. Mayer MM. Complement and complement fixation. In: Kabat EA, Mayer MM, eds. Experimental immunochemistry. Springfield, IL: CJ Thomas, 1961:133.
8. Schmid HW. Untersuchungen der Toxizität, der physikalisch-chemischen Eigenschaften und derhämolytischen Aktivität von trijodierten Röntgenkontrastmittel-Salzen in wäßrigen Lösungen. Pharma Acta Helv 1971;46:134-149,210-225,298-313.
9. Lang JH, Lasser EC, Kolb WP. Activation of serum complement by contrast media. Invest Radiol 1976;11:303-308.
10. Shugar D. The measurement of lysozyme activity and the ultraviolet inactivation of lysozyme. Biochim Biophys Acta 1952;8: 302.
11. Kim SH, Lee HK, Han MC. Incompatibility of water-soluble contrast media and intravascular pharmacologic agents. Invest Radiol 1992;27:45-49.
12. Krause W, Miklautz H, Kollenkirchen U, Heimann G. Physicochemical parameters of X-ray contrast media. Invest Radiol 1994;29:72-80.
13. Mützel W, Press WR, Weinmann HJ. Physicochemical properties and general pharmacology of the nonionic dimer iotrolan. In: Taenzer V, Wende S, eds. Recent developments in nonionic contrast media. Stuttgart, Germany: Georg Thieme Verlag, 1989;28-32.
14. Speck U. Contrast media: Overview, use and pharmaceutical aspects. Berlin Heidelberg, Germany: Springer Verlag, 1993.
15. Lorusso V, Poggesi I, Tirone P. Protein binding of iodinated contrast agents. Br J Radiol 1990;63:756-987.
16. Skinnemoen K. Physicochemical properties and degree of protein binding of iopentol. Acta Radiol 1987;370 (suppl):33-36.
17. Akagi M, Tasaka K. Comparative study of the adverse effects of various radiographic contrast media, including ioversol, a new low-osmolarity medium: I. Histamine release. Meth Find Exp Clin Pharmacol 1991;13:377-384.
18. Ennis M, Lorenz W, Nehring E, Schneider C. In vitro and in vivo studies of radiographic contrast media-induced histamine release in pigs. Agents Actions 1991;33:26-29.
19. Salem DN, Findlay SR, Isner JM, Konstam MA, Cohen PF. Comparison of histamine release effects of ionic and nonionic radiographic contrast media. Am J Med 1986;80:382-384.
20. Weiss HD, Jansen O, Schallock J, Schaubschläger WW. Plasmahistaminliberation nach Applikation von nicht-ionischen Kontrastmitteln. Fortschr Röntgenstr 1989;150:93-95.
21. Herd CM, Robertson AR, Frewin DB, Taylor WB. Adverse reactions during intravenous urography: Are these due to histamine release? Br J Radiol 1988;61:5-11.
22. Robertson PW, Frewin DB, Robertson AR, Mahar LJ, Jonsson JR. Plasma histamine levels following administration of radiographic contrast media. Br J Radiol 1985;58:1047-1051.
23. 2-receptor antagonists: Results of a prospective controlled trial. Int Archs Allergy Appl Immun 1985;78:9-14.
24. Pinet A, Corot C, Biot N, Eloy R. Evaluation of histamine release following intravenous injection of ionic and nonionic contrast media. Invest Radiol 1988;23:S174-S177.
25. Hasselbacher P, Hahn J. In vitro effects of radiographic contrast media on the complement system. J Allergy Clin Immunol 1980;66:217-222.
26. Parvez Z, Moncada R. Nonionic contrast medium: Effects on blood coagulation and complement activation in vitro. Angiology 1986;37:358-364.
27. Eaton S, Tsay HM, Yost F, Tweedle MF. Assays for plasma complement activation by x-ray contrast media. Invest Radiol 1990;25:789-792.
28. Westaby S, Dawson P, Turner MW, Pridie RB. Angiography and complement activation. Evidence for generation of a C3a anaphylatoxin by intravascular contrast agents. Cardiovasc Res 1985;19:85-88.
29. Freyria AM, Pinet A, Belleville J, Eloy R. Traeger J. Effects of five different contrast agents on serum complement and calcium levels after excretoty urography. J Allergy Clin Immunol 1982;69: 397-403.
30. Hoffmeister HM, Fuhrer G, Platten HP, Heller W. Changes in complement components after intravascular application of contrast media. Adv Exp Med Biol 1989;247B:585-589.
31. Gardinali M, Cicardi M, Agostoni A. Complement and contrast media reactions letter. Correspondence. Invest Radiol 1991;26: 918.
32. Hoffmeister HM, Fuhrer G, Pirschel J, Heller W. Veränderungen des Kallikrein-Kinin- und des Komplement-Systems bei Angiographien mit nichtionischen Kontrastmitteln. Klin Wochenschr 1988;66:760-763.
33. Georgsen J, Rasmussen F, Antonsen S, Larsen ML. Influence of radiographic contrast media on granulocyte enzymes and complement during uncomplicated urographies. Eur J Radiol 1991;12:63-66.
34. Parvez Z, Moncada R. Complement abnormalities during contrast media procedures. Immunopharmac 1985;7:123-127.
35. Gardinali M, Cicardi M, Frangi D, Franzinelli, Gattoni F, Uslenghi C, Agostoni A. In vivo study of the complement system during infusion of radiographic contrast media. J Allergy Clin Immunol 1986;77:690-692.
36. Akagi M, Masaki S, Kitazumi K, Mio M, Tasaka K. Comparative study of the adverse effects of various radiographic contrast media, including ioversol, a new low-osmolarity medium: II. The complement system and endothelial cells. Meth Find Exp Clin Pharmacol 1991;13:449-454.
37. Lasser EC, Slivka J, Lang JH, et al. Complement and coagulation: Causative considerations in contrast catastrophies. AJR Am J Roentgenol 1979;132:171-176.
38. Gonsette RE, Delmotte P. In vivo activation of serum complement by contrast media. Invest Radiol 1980;15:S26-S28.
39. Lieberman P. Anaphylactoid reactions to radio contrast material. Clin Rev Allergy 1991;9:319-338.
40. Shilvold A, Bjornsen S, Brosstad F. The effect of various contrast media on the activation of plasminogen by streptokinase or recombinant tissue plasminogen activator in vitro. Invest Radiol 1994;29:705-708.
41. Mützel W, Speck U. Tolerance and biochemical pharmacology of iopromide. In: Taenzer V, Zeitler E, eds. Contrast media in urography, angiography and computerized tomography. Stuttgart, Germany: Georg Thieme Verlag, 1983:11-17.
42. Lang JH, Lasser EC. Nonspecific inhibition of enzymes by organic CM. J Med Chem 1971;14:233-236.
43. Mancini GBJ, McGillem MJ. Papaverine as a coronary vasodilator. AJR Am J Roentgenol 1986;147:1095-1096.
44. Shah SJ, Gerlock AJ. Incompatibility of hexabrix and papaverine in peripheral arteriography. Radiology 1987;162:619-620.
45. Irving HD, Burbridge BE. Incompatibility of contrast agents with intravascular medications. Radiology 1989;173:91-92.
46. Zagoria RJ, D'souza VJ, Baker AL. Recommended precautions when using low-osmolality or nonionic contrast agents with vasodilators. Invest Radiol 1987;22:513-514.
47. McGill JE, Rysavy JA, Frick MP. Experimental investigations of the hexabrix-papaverine interaction. Radiology 1988;166:577-578.
48. Pallan TM, Wulkan IA, Abadir AR, Flores L, Chaudhry MR, Gintautas J. Incompatibility of Isovue 370 and papaverine in peripheral arteriography. Radiology 1993;187:257-259.
49. Rosati G, Morisetti P, Tirone P. Toxicity in animals and safety in humans: the predictive value of animal studies. Toxicology Letters 1992;64/65:705-15.